Dr. Prasanth Reddy, Head Oncology At LabCorp, he tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of a patient’s journey from testing to treatment.
The oncology sector has transformed over the past several decades thanks to the emergence of technological developments. Through partnerships and in-house innovation, LabCorp uses these advances to improve healthcare stakeholder experiences for better patient outcomes.
“Next to LabcorpWe innovate through science and technology, with access to nearly 2,500 [doctors] and PhD and more than 700 patients. This access allows us to support 82% of new drugs and FDA-approved therapeutic products, including 63% of those for oncology,” Reddy says.
Besides drugs and treatments, data collection and technological improvements have redefined the traditional healthcare experience, particularly in oncology, and genotyping has become an important factor in allowing personalized care.
Everyone’s genetic makeup is different, and each person’s cancer experience is unique — how the cancer develops, how quickly it spreads, which drugs it responds to, and more.
Cancer cells and tumors behave differently from normal cells and have changes in their genes that make them different from an individual’s normal cells. Furthermore, each cancer has different genetic alterations – also referred to as the genetic makeup of the cancer.
In other words, every cancer has its own genetic makeup. Personalized medicine researches the development or use of treatments that target those differences.
One of LabCorp’s groundbreaking tests, OmniSeq INSIGHT, Reddy says, is “a comprehensive test that includes comprehensive genomics and immunoprofiling from a single tissue sample to identify all FDA-approved therapies, confirm patient immunotherapy eligibility, and identify appropriate nearby clinical trials.”
The test informs health care providers with a comprehensive clinically and analytically validated genomic and immunophenotyping test for all solid tumors.
The results inform providers of the best treatment approaches, including targeted therapy and immunotherapy options to which an individual is likely to respond, and the mechanisms of low response and resistance to treatments based on the genetic and immunological profile of the patient’s tumor.
Says Reddy, “Other featured tests include clonoSEQ, the first and only FDA-approved test for detecting measurable residual disease, and Resolution ctDx Lung Assay, a liquid biopsy based on next-generation sequencing (NGS).” It allows you to evaluate all of the major mutation types involved in non-small cell lung cancer (NSCLC).”
“Testing is performed in the caregiver’s office or at our Patient Service Centers (PSC). Our PSCs combine blood tests and liquid biopsies for many advanced diagnostic NGS, such as IntelliGEN Myeloid, which evaluates 50 of the most clinically relevant genes mutated in myeloid malignancies. “.
Customized medicine that targets an individual’s genetic makeup or the genetic makeup of a cancer is beneficial and is now more widely available than ever before.
Providers create individualized treatment plans for their patients based on their genes, proteins, or other bodily substances, resulting in better, faster, and more effective patient outcomes.
Along with the technology LabCorp uses, the company is forging partnerships to expand its influence in the clinical trial space and allow its products and offerings to be distributed more widely.
Overcome barriers to reach
Customized medicine is very promising for oncology patients, but there is a downside to pursuing this type of treatment – the high cost.
Although the expenses associated with genome sequencing have fallen dramatically since the beginning of the field of genomics in the late 1980s, patients may still have difficulty paying for this type of personalized treatment.
Reddy says LabCorp has accelerated its global capabilities and innovations in cancer testing and partnerships with hospital systems, to lower the cost of high-quality patient care.
LabCorp recently acquired Personal Genome Diagnostics (PGDx), a leading cancer genomics company, with a range of liquid biopsies and tissue-based products.
“PGDx is one of the recent game-changing acquisitions in our fight against cancer, using liquid biopsy and tissue-based products to augment our capabilities with oncologists’ suite-based solutions, profiling tumor features that are detailed and actionable in hospitals or in our labs, and on the Global expansion of tumor profiling data,” Reddy says.
“They offer the only FDA-approved diagnostic kit for comprehensive tumor diagnosis of cancer using a genetic panel of more than 500. We are increasing access to oncology care in the global community with equipped solutions that allow hospital and laboratory systems to perform these tests in-house.”
The company also recently entered into a partnership with MD Anderson Cancer Center Madrid, where it will conduct clinical trials and provide access to new treatments for local cancer patients.
“Early-phase clinical research is the first step toward determining the safety and early efficacy of new therapies that can advance and address the unmet needs of treating patients with all types of cancers. [The] The MD Anderson Cancer Center in Spain is a world leader in conducting early clinical trials that could accelerate the availability of these life-saving treatments,” says Reddy.
“In recent years, innovative experimental designs have become an important component of the clinical development of oncology, especially early-stage tumor studies. Partnering with institutions such as MD Anderson, experienced in complex clinical trial designs, including platform studies, phase trials The first hybrids in equally complex fields of new oncology, and therapeutic development such as immuno-oncology, cytology, and gene therapyIt will allow us to develop cutting edge technologies and treatments. “
Reddy says the company has proprietary lab technology, powered by robotics and artificial intelligence (AI), to accurately perform hundreds of millions of tests.
With its extensive clinical data, the organization hopes to provide the answers and insights that will help move clinical trials forward faster.
“Knowledge can change the course of healthcare for all and change the course of care for individuals in need. By unlocking unprecedented data, tools, and technologies, we have seen evidence that every innovation leads to more answers and better lives for all,” says Reddy.
About the guest
Dr. Prasanth Reddy, MPH, FACP, is Senior Vice President and Global Head of Foundation Oncology at Labcorp. He has been instrumental in expanding Labcorp’s oncology portfolio and advancing precision oncology efforts. He received his medical degree from the University of Kansas and holds a triple board certification in internal medicine, oncology, and hematology. He holds a master’s degree in public health, a Harvard Business School graduate, and a fellow of the American College of Physicians.
About the author
Jessica Hagen is a freelance life sciences and health writer and project manager who has worked with medical extended reality (XR) companies, fiction/realism authors, nonprofit and for-profit organizations, and government agencies.